– BioCryst Pharmaceuticals Inc said it would withdraw an application to
test its experimental hepatitis C drug in humans after the U.S. Food
and Drug Administration expressed concern about its safety.
The FDA had concerns about the preclinical toxicity profile of the drug candidate, BCX5191, the company said.
drug belongs to a new class of hepatitis C treatments, known as nucs,
that is widely expected to be a game-changer in hepatitis C management
but has been plagued by safety concerns.